Skip to main content

Durect Value Stock - Dividend - Research Selection

Durect

ISIN: US2666051048, WKN: 564868

Market price date: 24.05.2021
Market price: 1,65 USD




Durect Fundamental data and company key figures of the share

Annual reports in USD
Key figures 07-03-2021
Cash flow
Net operating cash flow -38.704.000
Capital Expenditures -208.000
Free cash flow -38.912.000
Balance sheet
Total Equity 40.115.000
Liabilities & Shareholders equity 75.641.000
Income statement
Net income -582.000
Eps (diluted) -0,003
Diluted shares outstanding 199.457.000
Net sales/revenue 30.111.000

Fundamental ratios calculated on: 24-05-2021

Ratios
Key figures 24-05-2021
Cash flow
P/C -8,50
   
P/FC -8,46
Balance sheet
ROI-0,77
ROE53,03
Income statement
P/E-577,03
Div. Yield0,00%
P/B8,20
P/S10,93


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolDRRX
Market Capitalization329.104.064,00 USD
Country
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.durect.com


Description of the company

Durect Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms. The Company´s product pipeline, as of December 31, 2012, consisted of eight investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA), with one program in Phase III with an NDA in preparation, two programs in Phase II and three programs in Phase I. The Company´s products candidates include Remoxy, POSIDUR, ELADUR, TRANSDUR-Sufentanil, Relday, ORADUR-based opioid, ORADUR-ADHD, Relday and other products. The Company´s developments are focused on the application of its drug delivery technologies to potential products in a variety of chronic and episodic disease areas, including pain, central nervous system (CNS) disorders, cardiovascular disease and other chronic diseases.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.durect.com